OSE Immunotherapeutics to Host Key Opinion Leader Webcast on Lusvertikimab

Biotech firm OSE Immunotherapeutics will present clinical and development updates for its drug candidate lusvertikimab during a specialized webcast for key opinion leaders on September 2, 2026.